Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. by Helin, H. et al.
Br. J. Cancer (1990), 62, 109-112
Discordant results between radioligand and immunohistochemical assays
for steroid receptors in breast carcinoma
H. Helin, J. Isola, M. Helle & T. Koivula'
Department ofBiomedical Sciences, University of Tampere, PO Box 607, SF-33101 Tampere, and 'Department ofClinical
Chemistry, University Central Hospital of Tampere, SF-33520 Tampere, Finland.
Summary Surgical biopsy specimens of 179 breast carcinomas were studied by steroid-binding and
immunohistochemical assays or oestrogen and progesterone receptors (ER, PR) in order to explore reasons for
discordant results between the two assay types. Receptor statuses in 18% of ER assays and 30% of PR assays
were in disagreement. Immunohistochemistry-positive steroid-binding-negative status predominated among the
discordant ER assays, while the discordant PR assays displayed the opposite situation. In discordant assays
receptor concentration was significantly more often close to the cut-off (10-50fmolmg-') than in the
concordant ones. Low binding affinity (high Kd) was also significantly associated with disagreeing assay results.
These observations clearly indicate that immunohistochemical ER and PR assays measure high-affinity binding
components (i.e. type I receptors) in steroid-binding assays. ER but not PR assays in premenopausal women
disagreed more often than those in post-menopausal women. Such factors as histological type, specimen size in
steroid-binding assay, grade of malignancy and tumour necrosis were statistically unrelated to agreement or
disagreement of receptor assays.
Quantitation of radiolabelled oestrogen and progestin bound
to tumour extract cytosol is the established technique to
assay the receptors of these hormones in breast carcinoma
tissue (Jensen, 1978; McGuire & Clark, 1985). The results of
such determinations have been successfully used to predict
response to endocrine treatment. Moreover, steroid receptor
status has been found a valuable indicator of survival and
possibly of recurrence-free interval (McGuire, 1987; Fisher et
al., 1988; Thorpe, 1988).
Development of monoclonal antibodies to oestrogen and
progesterone receptors (ER, PR) has enabled the introduc-
tion of immunohistochemical assay (King et al., 1985, Perrot-
Applanat et al., 1987; Pertschuk et al., 1988) with some
potential advantages over the steroid-binding technique
(King et al., 1985; McCarty et al., 1985; Helin et al., 1988;
Kinsel et al., 1989). Results of the former assays, based on
immunological recognition of antigenic epitopes on receptor
molecules, have displayed moderate to excellent agreement
with those of the radioligand binding assays (McCarty et al.,
1985; King et al., 1985; Giri et al., 1988; Helin et al., 1989;
Pertschuk et al., 1988; Kinsel et al., 1989). However,
10-30% of the results have been discordant. This study
focuses on possible reasons for discordant results between
steroid binding and immunohistochemical assays in 179
consecutive surgical biopsy specimens of female breast car-
cinoma.
Patients, tumours and methods
Patients
Surgical biopsy specimens were obtained from 179 women
operated for primary breast carcinoma in 1986-1988.
Median age of the patients was 61 years (range 29-92).
Fifty-eight of the patients were pre- and 121 post-meno-
pausal. All patients with amenorrhoea of more than 2 years
were considered post-menopausal. When the cessation of
menstruation was unknown, women at > 52 years of age
were taken as post-menopausal.
Tumours
Breast carcinoma biopsy specimens were removed at opera-
tion and submitted for frozen section histopathological
analysis. The tissue block was examined by a pathologist and
divided into two portions. Both were frozen in liquid nitro-
gen within 15 min of removal. One portion was sectioned in
a cryostat at 4-61 m for intraoperative diagnosis, and for
immunohistochemical steroid receptor analysis. For the lat-
ter, the cryostat sections were attached to microscope slides
coated with poly-L-lysine (Sigma Chemical Co., St Louis,
MO, USA). The other portion of the tissue block was used
for radioligand binding assay of ER and PR. For both types
of receptor assay, the tissues were stored air-tight at -80°C
for no longer than 2 weeks.
Histopathological and immunohistochemical analysis
Tumour specimens were processed to paraffin sections and
stained using standard histological procedures. The tumours
were histologically classified according to the World Health
Organization (WHO) nomenclature (Hartmann et al., 1981)
and graded in three categories of malignancy as described by
Blood and Richardson (1957). The grading was based on
subjective estimation of tubule formation, nuclear atypism
and frequency of mitotic/hyperchromatic nuclear figures.
Also estimated were the occurrence of tumour necrosis,
epithelium to stroma ratio within the tumour (both scored
1-3) and relative cellularity of the tumour per total section
area (recorded as percentage).
Immunohistochemical determination of ER was performed
with the ER-ICA immunoperoxidase kit (Abbott Labora-
tories, Diagnostic Division, North Chicago, IL, USA) follow-
ing the manufacturer's instructions. MCF-7 cells were used
as positive controls. In the negative control staining, normal
rat immunoglobulin replaced the monoclonal anti-ER.
PR was detected on cryostat sections using a monoclonal
mouse antibody to rabbit uterine PR (Transbio, Paris,
France) known to crossreact with human PR (Logeat et al.,
1983). The detailed immunoperoxidase staining procedure
has been described earlier (Helin et al., 1988a, 1989). Frozen
sections of rabbit uterus were used as positive controls, and
negative control staining was done using non-immune mouse
immunoglobulin instead of the specific antibody.
The immunoperoxidase stainings for ER and PR were
semiquantitatively assessed as described by McCarty et al.
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(1985). Each stained section was given a histoscore (hs, range
0-500) calculated from the formula: I:(i + 1) x P,, in which
i= intensity of nuclear staining (1-4, 0 = no staining) and
Pi= percentage of stained nuclei of carcinoma cells. On the
grounds of our earlier studies, an hs > 100 was considered
positive for ER and an hs > 40 positive for PR (Helin et al.,
1988a, 1989).
Steroid-binding assay
The concentrations of ER and PR in tumour extract cytosols
were determined by a radioligand binding assay using multi-
point titration with seven different concentrations of tritiated
estradiol or Org 2058 as ligands. Dextran-coated charcoal
(DCC) was used to separate protein-bound from free tritiated
hormones (Vihko et al., 1980). After counting of radio-
activity, the binding data and dissociation constants (Kd)
were calculated by the method of Scatchard (1949). Non-
specific binding was corrected by means of a computer pro-
gram (Isola et al., 1988). Values equal to or higher than
10 fmol of bound 3H-oestrogen or progestin were regarded as
positive. Assays with Kdk0.2 nM (ER) or ) 0.3 nM (PR)
were scored negative except for the data in Figure 3, where
the cut-off in receptor concentration was the only criterion
for positivity.
Statistical analyses
The concordance between the immunohistochemical and
steroid-binding assays was assessed with the kappa statistics
(Fleiss, 1981) in which a kappa-coefficient = 0 indicates
chance agreement and a kappa = 1 designates full agreement.
The kappa test, one-way analysis ofvariance, and the X2 tests
were calculated with the Biomedical Data Processing Soft-
ware Library (BMDP, Los Angeles, CA, USA).
Results
Comparison ofimmunohistochemical receptor determination
with steroid-binding assay
The two different assays, based on either radioligand binding
or on immunoperoxidase location of tissue-bound mono-
clonal antibodies, are compared in Table I. The receptor
statuses (positive or negative), defined by the two assays,
agreed in 82 (ER) or 70 (PR) % of the cases. The kappa-
coefficient (95% confidence limits) for ER comparisons was
0.585 (0.521, 0.649), and for those PR 0.4 (0.331, 0.469). The
immunohistochemical ER assay was somewhat more often
positive than the biochemical one (123 vs 116). Among the
discordant cases, those positive in immunohistochemistry and
negative in DCC assay predominated. In PR determinations,
the DCC assay was a little more often positive (105 vs 96),
and DCC-positive, immunoperoxidase-negative assay results
were the predominant discordant ones (Table I).
The results of steroid-binding assays were divided into
three categories (receptor concentration < 10, 10-50,
>50 fmol mg-'). Discordant assay results were significantly
less likely to occur with assays giving cytosol concentrations
>50fmolmg-' (X2 test for linear trends: ER, P<0.0001;
PR, P=0.029; Figure la). Similarly categorised histoscores
(<100 (ER) or <40 (PR), 100-250, >250) are correlated
to discordance in Figure lb. Discordant assay results are rare
in tumours with high histoscores (X2 test for linear trends:
ER, P=0.009; PR, P=0.011).
Influence ofendocrine status
The results of the two ER assays disagreed significantly more
often in premenopausal (n = 58) than in post-menopausal
(n = 121) patients (X2 test, P = 0.03; Figure 2). Both types of
discordance (DCC - /histo + and DCC + /histo -) were
equally represented among the premenopausal patients. In
Table I Comparison ofimmunohistochemical ER and PRdetermina-
tions (ERh,, PRhJ) with cytosol steroid-binding assay (ERC, PRV) in 179
breast carcinomasab
ERC- ERC +
(<JIOfmolmg') (> lOfmolmg) Total
ERhS- (<100) 43 13 56
ERhS+ (>100) 20 103 123
Total 63 116 179
PRC- PRC+
(<IOfmolmg-') (>IOfmolmg') Total
PRhS- (<40) 52 31 83
PRhS+ (>40) 22 74 96
Total 74 105 179
aKappa-coefficient = 0.585 (ER), 0.4 (PR). bassays with Kd >0.2 nM
(ER) or >0.3 nM (PR) were scored negative.
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Figure 1 Relative proportions of concordant and discordant
results between steroid-binding and immunohistochemical recep-
tor assays as functions of cytosol receptor concentration (a) or
immunohistochemical score (b). Discordant results are rare in
assays with high cytosol receptor concentrations (a) or histo-
scores (b). Note the high percentage of discordant assays in the
DCC PR assay range 10-50 fmol mg- (a). Histoscore groups:
negative, < 100 (ER) or <40 (PR); positive, 100-250; strong
positive, >250 (b). Total number of tumours in each group is
given above the bars. In both comparisons, the differences
between the three groups are statistically significant (X2 test for
linear trends).
the two PR assays there was no such difference (P = 0.6;
Figure 2).
Influence ofdissociation constant
The results of the radioligand assay were divided into three
groups on the basis of the binding affinity (high, medium,
low binding affinity), as reflected by the dissociation constant
(KId). Concordant results were highly significantly associated
with high and medium binding affinity (low and medium Kd;
X2 test for linear trends: ER, P<0.0001; PR, P=0.0017, Figure 3), whereas low binding affinity was often associated
with discordance between the two assays. Further, the dis-
sociation constant was associated with the patients' endocrine
status. Post-menopausal status was more likely to associate
with lower Kd values (higher binding affinity) than the pre-
menopausal one (x2 test for linear trends: ER, P = 0.0002;
PR, P = 0.0007).
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Figure 2 Proportions of concordant and discordant assay results
as functions of endocrine status. Discordant ER results are
relatively more frequent in premenopausal patients (P = 0.03, x2
test). In PR determinations there is no significant difference.
Total number of tumours in each group is given above the bars.
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Figure 3 Proportions of concordant and discordant ER and PR
assay results as functions of binding affinity (Kd) in steroid-
binding assay (Kd groups for ER: high, <0.1; medium 0.1-0.2;
low, >0.2 nM; for PR: <0.1, 0.1 -0.3, >0.3 nM). Concordant
assays are associated with medium and high binding affinity (low
Kd). Total number of tumours in each group is given above the
bars. Cut-off in receptor concentration was the only criterior for
positivity in DCC assays. The differences between the three
groups are statistically significant (x2 test for linear trends).
Otherfactors
The epithelial cell content of the tumours (reflected by the
epithelium to stroma ratio) displayed a significant association
with concordance in ER assays. The assay results were more
likely to agree in tumours with high content of malignant
epithelium (epithelium to stroma ratio score 3; x2 test for
linear trends: P = 0.035). Cellularity of the tumours (propor-
tion of tumour epithelium in the microscopic section) was
estimated in the frozen section (median 25%, range 5-75)
and was not statistically associated with concordance.
Unrelated to the likelihood of discordance or concordance
were such factors as the histologic type of the tumour, grade
of malignancy and tumour necrosis. Neither was the size of
the tumour specimen (median 500 mg, range 100-1,480)
associated with agreement or disagreement between the assay
results.
Discussion
The results of the steroid-binding and immunohistochemical
assays displayed a moderate to good agreement. The receptor
status disagreed in 18 (ER) or 30 (PR) % of patients. Similar
rates of concordance have been reported in ER studies by
other investigators (McCarty et al., 1985; King et al., 1985;
Hanna & Mobbs, 1989; Kinsel et al., 1989). Immunohisto-
chemical studies on PR in breast carcinoma are much fewer.
Using the same monoclonal anti-PR antibody, mPRI, Perrot-
Applanat et al. (1987) in a preliminary study, and Giri et al.
(1988) observed a better concordance with DCC assays (92
and 86% agreement). Pertschuk et al. (1988) used the mono-
clonal anti-human PR antibody JZB 39 and found an agree-
ment of 76 or 54% in two sets of breast carcinoma biopsy
material. In our previous studies, the agreement has been
71-76% with the mPRI (Helin et al., 1988a, 1989), and 82%
with the JZB 39 antibody (Isola et al., 1990).
Among the discordant assay results, the immunohisto-
chemistry-positive DCC-negative status predominated in ER
determinations. This might be due to erroneously negative
results in ER DCC assays, since false positive nuclear
immunostaining seems very unlikely in adequately controlled
immunohistochemical analysis. Most likely to contribute to
these false negative results are ER assays in premenopausal
women (see below). In PR assays the predominant discordant
status was the immunohistochemistry-negative DCC-positive
one. One reason for these 31 discordant assay results could
be insensitive receptor detection by the monoclonal antibody
leading to false negative immunohistochemical results. How-
ever, we have compared the monoclonal mouse anti-rabbit
PR antibody used here with the recently introduced JZB 39
anti-human PR antibody and obtained results which were
only slightly in favour of the latter (Isola et al., 1989).
Figure 1 in our study shows that the immunohistochemical
and steroid-binding assays disagreed often when either of
them yielded low receptor contents. There were virtually no
discordant results when the ER concentration was > 50 fmol
mg-', or when ER or PR histoscores were >250. Eighty per
cent of the results disagreed when the cytosol PR concentra-
tion was 10-50 fmol mg-'. These results suggest that low
receptor contents, especially low PR concentrations, should
be taken with care as predictors of therapy response and
survival. A recent prognosis study with over 1,000 patients
and a follow-up of 60 months (Shek & Godolphin, 1989)
demonstrated in an analysis with stratified ER DCC data
that high ER levels were significantly associated with pro-
longed survival.
Kinsel et al. (1989) reported better predictive value for
immunohistochemical ER determination relative to steroid-
binding assay. They stated that in the steroid-binding assays
more of the negative results were in the borderline range than
in the immunohistochemistry. Non-receptor steroid-binding
proteins or low levels of ligand binding to nonmalignant
tissue components were discussed as possible reasons.
Endocrine status is clearly associated with the likelihood of
discordance between the two assay types but only in ER
determinations. In this study we confirmed our previous
result (Helin et al., 1988b) that ER assays are more often
concordant in post-menopausal than in premenopausal
patients. Interference ofendogenous oestrogen with the DCC
assay is one possible explanation. To support this, high
plasma or serum oestradiol levels have been observed to
associate with low ER concentrations (Nagai et al., 1979;
Helin et al., 1988b). Other investigators have found no such
association (Fishman et al., 1977; Edery et al., 1981). Rather
than being due to occupation of ER by endogenous ligands,
low ER concentrations in premenopausal patients have been
examined by true down-regulation of ER synthesis in a
number of studies (e.g. Saez et al., 1978). The latter include
demonstration of low ER mRNA levels in premenopausal
breast carcinoma tissue (Barret-Lee et al., 1987). Some
immunohistochemical studies have also yielded lower con-
tents of ER in receptor-positive premenopausal specimens
(King et al., 1985). The higher discordance between the assay
results in premenopausal patients may thus partly reflect its
dependence on receptor concentration.
Immunohistochemical ER and PR results correlated poorly
with DCC values having high KI. High Kd values may be a
result of erroneous interpretation of Scatchard plots or of the
presence of a second steroid-binding molecule ('type II recep-
tor'). Our results indicate that the immunohistochemical ER
and PR assays recognise the high affinity steroid binding
component ('type I receptor').
Potential sources of discrepancy between the two assay
types and sources of error in the DCC assay are the absence
of malignant tissue and receptor heterogeneity in the test
sample. Thorpe (1987) and Steele et al. (1987) reported sur-
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prisingly high proportions of histologically unsatisfactory
tumour specimens. In our study cellularity per frozen section
(proportion of malignant epithelium of total sample tissue)
was not related to concordance/discordance. Low epithelial
cell content within the tumours was, however, significantly
correlated with discordance confirming that specimens with
small amounts of carcinoma cells are a problem encountered
in DCC assays.
Intratumour heterogeneity in receptor expression has been
demonstrated by multiple sampling in numerous DCC stud-
ies (e.g. Davis et al., 1984), and it is clearly visualised in
immunohistochemical analysis. High histoscore values corre-
spond to little heterogeneity in receptor expression and they
were correlated with high degree of concordance between the
two assay types in our work (Figure lb).
Subjectivity of interpretation may interfer with semiquan-
titative immunohistochemical analysis similarly to conven-
tional morphological examination. The latter has displayed
unexpectedly low interobserver reproducibility in some
studies on breast carcinoma histopathology (Gilchrist et al.,
1985; Davis et al., 1986). Computerised image analysis may
increase the objectivity of immunohistochemical analysis.
Studies focused on therapy response and survival are need-
ed to assess the biological relevance and clinical value of
immunohistochemical steroid receptor determination and its
usefulness in comparison with conventional steroid-binding
assay. In particular, the predictive value of receptor hetero-
geneity, revealed by routine immunohistochemical analysis, is
of interest.
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